Adriamycin, ADRIBLASTINA, FARMIBLASTINA

SECTION 2: Hazards identification

Appearance: Red solution

Signal word

DANGER

Hazard statements

May damage fertility or the unborn child. May cause cancer. May cause genetic defects.

Additional information

Short Term: May cause eye and skin irritation (based on components) . Effects of ingestion are not known. Avoid swallowing this material. Drugs of this class have been associated with rare, but potentially serious cardiac events. These events have not been observed from occupational exposures, however, those with preexisting cardiovascular illnesses may be at increased risk from exposure. Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on testes, the developing fetus. Known Clinical Effects: Bone marrow suppression is the most serious adverse effect seen during clinical use. EU Indication of danger: Mutagenic: Category 2 Carcinogenic: Category 2 Toxic to Reproduction: Category 2 EU Hazard Symbols: EU Risk Phrases: R45 - May cause cancer. R46 - May cause heritable genetic damage. R60 - May impair fertility. R61 - May cause harm to the unborn child. Australian Hazard Classification

Hazardous Ingredients

Non-Dangerous Goods (NOHSC): Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.